Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | THINK trial: Phase I results for NKG2D CAR-T therapy in AML

David Sallman • 17 Dec 2018
ASH 2018
Acute Myeloid Leukemia Leukemia CAR-T CYAD-01 Tocilizumab
THINK

CYAD-01 is a CAR T-cell product based on the Natural Killer Group 2D (NKG2D) receptor. Here, David Sallman, MD, of the Moffitt Cancer Center, Tampa, FL, discusses the latest data presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, on the Phase I dose escalation THINK trial (NCT03018405), assessing the safety and clinical activity of multiple CYAD-01 administrations without prior preconditioning.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from David Sallman

Novel targets for T-cell engagers in relapsed/refractory AML
10:17
Novel targets for T-cell engagers in relapsed/refractory AML
David Sallman • 19 Sep 2026
Phase IIa trial of ofirnoflast, a first-in-class allosteric NEK7 inhibitor, in ESA-refractory LR-MDS
7:19
Phase IIa trial of ofirnoflast, a first-in-class allosteric NEK7 inhibitor, in ESA-refractory LR-MDS
David Sallman • 1 Oct 2026
Lessons from Phase I KITE-222: antigen escape, expansion, and the future of CAR-T in AML
4:14
Lessons from Phase I KITE-222: antigen escape, expansion, and the future of CAR-T in AML
David Sallman • 1 Oct 2026
Lessons from Phase III ENHANCE: TP53, transplant, and MRD in future HR-MDS combination trials
4:28
Lessons from Phase III ENHANCE: TP53, transplant, and MRD in future HR-MDS combination trials
David Sallman • 1 Oct 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals